Evaluate growth strategies by getting insights into regional segments - Request a sample now!
Anti-nuclear Antibody Testing Market: Segmentation Analysis
The market research report segments the anti-nuclear antibody testing market by End User (hospitals and clinical diagnostic laboratories) and Geographic (North America, Europe, Asia, and ROW).
- Revenue Generating Segment -The global anti-nuclear antibody testing market share growth by the hospital's segment will be significant for revenue generation. Large hospitals such as multispecialty hospitals and hospital groups work through government sponsorships or private entities. They obtain medical products and consumables in bulk and engage with reimbursement authorities, suppliers, and government organizations. These hospitals have more than 600 hospital beds. They offer inpatient and outpatient services to generate more revenue, thereby driving the demand for this segment.
To know about the accurate prediction of the contribution of all the segments - Grab a sample!
Anti-nuclear antibody testing market: Major Driver
- The increasing number of autoimmune diseases is one of the key factors driving the growth of the global anti-nuclear antibody (ANA) testing market.
- Autoimmune diseases can affect any organ or system in the body, and the symptoms vary among different disease types. There are about 80 types of autoimmune diseases worldwide. Rheumatoid arthritis, Lupus, Celiac disease, and multiple sclerosis are some of the autoimmune diseases. For instance, the prevalence of rheumatoid arthritis varies from one region to another. It is one of the leading causes of morbidity in high-income countries, such as the US and Germany. Similarly, SLE is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissues. Moreover, type 1 diabetes is a localized autoimmune disease. It occurs due to the specific destruction of insulin-producing cells of the pancreas.
- However, the high incidence of type 1 diabetes indicates the demand for ANA testing during the forecast period. The growing demand for POC testing for diabetes management is expected to change the market dynamics, owing to its ability to diagnose quickly. Also, there have been growing initiatives in emerging economies such as India to develop non-invasive and affordable diagnostic tests for type 1 diabetes.
Anti-nuclear antibody testing market: Major Trend
- The shift from monoplex to multiplex testing will fuel the global anti-nuclear antibody (ANA) testing market.
- The focus on multiplex testing is increasing, particularly in the area of IVD, owing to the increased need for effective diagnosis. Autoimmune diseases are chronic conditions that collectively affect around 5% to 8% of the US population. Individuals who develop the organ-specific autoimmune disease have a high likelihood of developing additional autoimmune disorders. This has fueled the need for new technologies that can evaluate multiple immune reactivities in a small sample volume.
- Multiplexed assays can analyze samples by detecting multiple analytes from single or multiple samples, offering a high-throughput solution. Further, the newly developed multiplex immunoassay allows the simultaneous determination of different autoantibodies. These multiplexed systems are cost-effective, require limited labor, and offer increased efficiency and turnaround time in the delivery of results. Vendors are continuously developing novel products to meet the demand for rapid and efficient diagnostic systems. Such developments present a favorable landscape for the shift from monoplex testing to multiplex testing worldwide.
Refine your marketing strategies by knowing more about drivers & challenges - Request a sample report now!
Related Reports:
- The cryostat market share is expected to increase to USD 861.81 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.33%
- The spatial genomics and transcriptomics market share is expected to increase to USD 401.47 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 9.06%.
Global Anti-nuclear Antibody Testing Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2020 |
Forecast period |
2021-2025 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7% |
Market growth 2021-2025 |
USD 362.3 million |
Market structure |
Fragmented |
YoY growth (%) |
6.70 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 38% |
Key consumer countries |
US, Germany, France, UK, and Japan |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Abbott Laboratories, Abcam Plc, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Immuno Concepts Ltd., Merck KGaA, PerkinElmer Inc., Seramun Diagnostica GmbH, Thermo Fisher Scientific Inc., and Trinity Biotech Plc |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Content
1 Executive Summary
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 01: Parent market
- Exhibit 02: Market characteristics
- 2.2 Value chain analysis
- Exhibit 03: Value chain analysis for life sciences tools and services
3 Market Sizing
- 3.1 Market definition
- Exhibit 04: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 05: Market segments
- 3.4 Market outlook: Forecast for 2020 - 2025
- Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
- Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
- 4.1 Five forces summary
- Exhibit 08: Five forces analysis 2020 & 2025
- 4.2 Bargaining power of buyers
- Exhibit 09: Bargaining power of buyers
- 4.3 Bargaining power of suppliers
- Exhibit 10: Bargaining power of suppliers
- 4.4 Threat of new entrants
- Exhibit 11: Threat of new entrants
- 4.5 Threat of substitutes
- Exhibit 12: Threat of substitutes
- 4.6 Threat of rivalry
- Exhibit 13: Threat of rivalry
- 4.7 Market condition
- Exhibit 14: Market condition - Five forces 2020
5 Market Segmentation by End-user
- 5.2 Comparison by End-user
- 5.3 Hospitals - Market size and forecast 2020-2025
- Exhibit 17: Hospitals - Market size and forecast 2020-2025 ($ million)
- Exhibit 18: Hospitals - Year-over-year growth 2020-2025 (%)
- 5.4 Clinical diagnostic laboratories - Market size and forecast 2020-2025
- Exhibit 19: Clinical diagnostic laboratories - Market size and forecast 2020-2025 ($ million)
- Exhibit 20: Clinical diagnostic laboratories - Year-over-year growth 2020-2025 (%)
- 5.5 Market opportunity by End-user
- Exhibit 21: Market opportunity by End-user
6 Customer landscape
7 Geographic Landscape
- 7.1 Geographic segmentation
- Exhibit 23: Market share by geography 2020-2025 (%)
- 7.2 Geographic comparison
- Exhibit 24: Geographic comparison
- 7.3 North America - Market size and forecast 2020-2025
- Exhibit 25: North America - Market size and forecast 2020-2025 ($ million)
- Exhibit 26: North America - Year-over-year growth 2020-2025 (%)
- 7.4 Europe - Market size and forecast 2020-2025
- Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million)
- Exhibit 28: Europe - Year-over-year growth 2020-2025 (%)
- 7.5 Asia - Market size and forecast 2020-2025
- Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million)
- Exhibit 30: Asia - Year-over-year growth 2020-2025 (%)
- 7.6 ROW - Market size and forecast 2020-2025
- Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million)
- Exhibit 32: ROW - Year-over-year growth 2020-2025 (%)
- 7.7 Key leading countries
- Exhibit 33: Key leading countries
- 7.8 Market opportunity by geography
- Exhibit 34: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
- 8.2 Market challenges
- Exhibit 35: Impact of drivers and challenges
9 Vendor Landscape
- 9.2 Vendor landscape
- Exhibit 36: Vendor landscape
- 9.3 Landscape disruption
- Exhibit 37: Landscape disruption
- Exhibit 38: Industry risks
10 Vendor Analysis
- 10.1 Vendors covered
- Exhibit 39: Vendors covered
- 10.2 Market positioning of vendors
- Exhibit 40: Market positioning of vendors
- 10.3 Abbott Laboratories
- Exhibit 41: Abbott Laboratories - Overview
- Exhibit 42: Abbott Laboratories - Business segments
- Exhibit 43: Abbott Laboratories - Key news
- Exhibit 44: Abbott Laboratories - Key offerings
- Exhibit 45: Abbott Laboratories - Segment focus
- 10.4 Abcam Plc
- Exhibit 46: Abcam Plc - Overview
- Exhibit 47: Abcam Plc - Product and service
- Exhibit 48: Abcam Plc – Key news
- Exhibit 49: Abcam Plc - Key offerings
- 10.5 Bio-Rad Laboratories Inc.
- Exhibit 50: Bio-Rad Laboratories Inc. - Overview
- Exhibit 51: Bio-Rad Laboratories Inc. - Business segments
- Exhibit 52: Bio-Rad Laboratories Inc. – Key news
- Exhibit 53: Bio-Rad Laboratories Inc. - Key offerings
- Exhibit 54: Bio-Rad Laboratories Inc. - Segment focus
- 10.6 F. Hoffmann-La Roche Ltd.
- Exhibit 55: F. Hoffmann-La Roche Ltd. - Overview
- Exhibit 56: F. Hoffmann-La Roche Ltd. - Business segments
- Exhibit 57: F. Hoffmann-La Roche Ltd. - Key offerings
- Exhibit 58: F. Hoffmann-La Roche Ltd. - Segment focus
- 10.7 Immuno Concepts Ltd.
- 10.8 Merck KGaA
- Exhibit 62: Merck KGaA - Overview
- Exhibit 63: Merck KGaA - Business segments
- Exhibit 64: Merck KGaA – Key news
- Exhibit 65: Merck KGaA - Key offerings
- Exhibit 66: Merck KGaA - Segment focus
- 10.9 PerkinElmer Inc.
- Exhibit 67: PerkinElmer Inc. - Overview
- Exhibit 68: PerkinElmer Inc. - Business segments
- Exhibit 69: PerkinElmer Inc. – Key news
- Exhibit 70: PerkinElmer Inc. - Key offerings
- Exhibit 71: PerkinElmer Inc. - Segment focus
- 10.10 Seramun Diagnostica GmbH
- Exhibit 72: Seramun Diagnostica GmbH - Overview
- Exhibit 73: Seramun Diagnostica GmbH - Product and service
- Exhibit 74: Seramun Diagnostica GmbH - Key offerings
- 10.11 Thermo Fisher Scientific Inc.
- Exhibit 75: Thermo Fisher Scientific Inc. - Overview
- Exhibit 76: Thermo Fisher Scientific Inc. - Business segments
- Exhibit 77: Thermo Fisher Scientific Inc. – Key news
- Exhibit 78: Thermo Fisher Scientific Inc. - Key offerings
- Exhibit 79: Thermo Fisher Scientific Inc. - Segment focus
- 10.12 Trinity Biotech Plc
- Exhibit 80: Trinity Biotech Plc - Overview
- Exhibit 81: Trinity Biotech Plc - Product and service
- Exhibit 82: Trinity Biotech Plc - Key offerings
11 Appendix
- 11.2 Currency conversion rates for US$
- Exhibit 83: Currency conversion rates for US$
- 11.3 Research methodology
- Exhibit 84: Research Methodology
- Exhibit 85: Validation techniques employed for market sizing
- Exhibit 86: Information sources
- 11.4 List of abbreviations
- Exhibit 87: List of abbreviations
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article